Muscular dystrophies are hereditary diseases that are characterized by progressive muscle weakness and muscle atrophy. They belong to a group of neuromuscular diseases which include hereditary and acquired diseases of the peripheral neuromuscular system including involvement of the cells of the anterior horns of the spinal cord, peripheral nerves, neuromuscular junctions and muscles. The different forms vary according to the clinical picture, the rate of progression of the clinical picture, the pathological changes of the muscles, the mode of inheritance and the age of onset of symptoms. Duchenne muscular dystrophy (DMD) is the most common childhood muscular dystrophy affecting boys. The disease itself begins to manifest around the age of three. The first symptoms are related to gait, and the cause is symmetrical muscle weakness of the pelvic and shoulder hoops. The muscle weakness causes slower movements, difficulty performing activities that require joint action by muscle groups such as climbing stairs, getting up from the floor, lifting things overhead etc. Finger gait, gagging, Gowers’ sign, increased lumbar lordosis, and pseudohypertrophy of the lower leg muscles are present. The weakness gradually spreads from the lower to the upper extremities, neck, and respiratory muscles. The aim of this paper is to present Duchenne muscular dystrophy and its treatment with special emphasis on the treatment of the early stage of independent walking. Early stage treatment involves maintaining strength in the proximal extremity muscles, i.e. the pelvic and shoulder girdles, preventing or slowing further loss of muscle strength, and maintaining strength in the muscles that are essential for maintaining balance.